IL161352A0 - Methods and compositions for targeting underglycosylated proteins across the blood brain barrier - Google Patents
Methods and compositions for targeting underglycosylated proteins across the blood brain barrierInfo
- Publication number
- IL161352A0 IL161352A0 IL16135202A IL16135202A IL161352A0 IL 161352 A0 IL161352 A0 IL 161352A0 IL 16135202 A IL16135202 A IL 16135202A IL 16135202 A IL16135202 A IL 16135202A IL 161352 A0 IL161352 A0 IL 161352A0
- Authority
- IL
- Israel
- Prior art keywords
- targeting
- compositions
- methods
- brain barrier
- blood brain
- Prior art date
Links
- 230000008499 blood brain barrier function Effects 0.000 title 1
- 210000001218 blood-brain barrier Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32965001P | 2001-10-16 | 2001-10-16 | |
| US10/136,841 US7396811B2 (en) | 2001-04-30 | 2002-04-30 | Subcellular targeting of therapeutic proteins |
| US10/136,639 US20030072761A1 (en) | 2001-10-16 | 2002-04-30 | Methods and compositions for targeting proteins across the blood brain barrier |
| US38445202P | 2002-05-29 | 2002-05-29 | |
| US38601902P | 2002-06-05 | 2002-06-05 | |
| US40881602P | 2002-09-06 | 2002-09-06 | |
| PCT/US2002/032968 WO2003032727A1 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161352A0 true IL161352A0 (en) | 2004-09-27 |
Family
ID=27558195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16135202A IL161352A0 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1446007A4 (enExample) |
| JP (2) | JP2005506340A (enExample) |
| AU (3) | AU2002362930A2 (enExample) |
| CA (1) | CA2463473A1 (enExample) |
| IL (1) | IL161352A0 (enExample) |
| WO (2) | WO2003032913A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158623A0 (en) | 2001-04-30 | 2004-05-12 | Symbiontics Inc | Subcellular targeting of therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| AU2002362930A2 (en) * | 2001-10-16 | 2003-04-28 | Zystor Therapeutics, Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| AU2003237314B2 (en) * | 2002-05-29 | 2010-03-04 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
| US20050244400A1 (en) * | 2004-02-10 | 2005-11-03 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| EP2997976A1 (en) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| EP2234600B1 (en) * | 2007-12-21 | 2014-08-20 | F. Hoffmann-La Roche AG | Antibody formulation |
| HUE034850T2 (en) | 2008-05-07 | 2018-03-28 | Biomarin Pharm Inc | Lysosomal targeting peptides and their use |
| EP3679942A1 (en) | 2009-06-17 | 2020-07-15 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| WO2011044542A1 (en) | 2009-10-09 | 2011-04-14 | Armagen Technologies, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| IL291554B2 (en) | 2010-06-25 | 2024-02-01 | Shire Human Genetic Therapies | Administering therapeutic agents to the central nervous system |
| WO2011163652A2 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
| MX2013000320A (es) | 2010-06-25 | 2013-06-05 | Shire Human Genetic Therapies | Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa. |
| ME03649B (me) | 2010-06-25 | 2020-07-20 | Shire Human Genetic Therapies | Postupci i kompozicije za isporuku iduronat-2-sulfataze u cns |
| MX382443B (es) | 2010-06-25 | 2025-03-11 | Shire Human Genetic Therapies | Una formulación estable para usarse en el tratamiento de la enfermedad por leucodistrofia metacromática (mld). |
| PE20130589A1 (es) | 2010-06-25 | 2013-05-19 | Shire Human Genetic Therapies | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a |
| HK1200189A1 (en) * | 2011-12-01 | 2015-07-31 | 安吉奥开米公司 | Targeted lysosomal enzyme compounds |
| WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| US9687561B2 (en) | 2012-08-14 | 2017-06-27 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
| KR102521039B1 (ko) | 2012-11-27 | 2023-04-12 | 바이오마린 파머수티컬 인크. | 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들 |
| KR20150132332A (ko) | 2013-03-15 | 2015-11-25 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 저농도 항체 제형 |
| CA2943140A1 (en) | 2014-04-01 | 2015-10-08 | Swedish Orphan Biovitrum Ab (Publ) | Modified sulfamidase and production thereof |
| CN107921143B (zh) | 2015-06-15 | 2021-11-19 | 安吉奥开米公司 | 用于治疗软脑膜癌病的方法 |
| AU2017222620B2 (en) | 2016-02-24 | 2022-06-16 | Biomarin Pharmaceutical Inc. | Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof |
| US10874750B2 (en) | 2018-04-30 | 2020-12-29 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
| WO2020077114A2 (en) | 2018-10-10 | 2020-04-16 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
| WO2020132452A1 (en) | 2018-12-20 | 2020-06-25 | Shire Human Genetic Therapies, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| AU6501390A (en) * | 1989-09-21 | 1991-04-18 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| US6472140B1 (en) * | 1997-09-05 | 2002-10-29 | The General Hospital Corporation | α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease. |
| IL158623A0 (en) * | 2001-04-30 | 2004-05-12 | Symbiontics Inc | Subcellular targeting of therapeutic proteins |
| AU2002362930A2 (en) * | 2001-10-16 | 2003-04-28 | Zystor Therapeutics, Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| AU2003237314B2 (en) * | 2002-05-29 | 2010-03-04 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
-
2002
- 2002-10-16 AU AU2002362930A patent/AU2002362930A2/en not_active Abandoned
- 2002-10-16 JP JP2003535542A patent/JP2005506340A/ja active Pending
- 2002-10-16 IL IL16135202A patent/IL161352A0/xx unknown
- 2002-10-16 CA CA002463473A patent/CA2463473A1/en not_active Abandoned
- 2002-10-16 WO PCT/US2002/032996 patent/WO2003032913A2/en not_active Ceased
- 2002-10-16 AU AU2002347910A patent/AU2002347910A1/en not_active Abandoned
- 2002-10-16 EP EP02801739A patent/EP1446007A4/en not_active Withdrawn
- 2002-10-16 WO PCT/US2002/032968 patent/WO2003032727A1/en not_active Ceased
-
2009
- 2009-06-16 JP JP2009143436A patent/JP2009203241A/ja active Pending
-
2010
- 2010-08-25 AU AU2010214643A patent/AU2010214643A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003032913A9 (en) | 2004-04-29 |
| EP1446007A1 (en) | 2004-08-18 |
| AU2010214643A1 (en) | 2010-09-16 |
| JP2009203241A (ja) | 2009-09-10 |
| WO2003032913A3 (en) | 2004-08-12 |
| JP2005506340A (ja) | 2005-03-03 |
| WO2003032727A1 (en) | 2003-04-24 |
| CA2463473A1 (en) | 2003-04-24 |
| AU2002362930A2 (en) | 2003-04-28 |
| EP1446007A4 (en) | 2005-12-07 |
| WO2003032913A2 (en) | 2003-04-24 |
| AU2002347910A1 (en) | 2003-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161352A0 (en) | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier | |
| PT1757606E (pt) | Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação | |
| IL160001A0 (en) | Peptide based multimeric targeted contrast agents and methods for the preparation thereof | |
| GB0101990D0 (en) | Surgical system | |
| EP1391209A4 (en) | PROTEIN PREPARATION | |
| GB0104534D0 (en) | Pharmaceutical combination | |
| IL160998A0 (en) | Human tissue factor antibodies | |
| GB0124523D0 (en) | Pharmaceutical combination | |
| GB0118383D0 (en) | Therapeutic methods | |
| GB0129270D0 (en) | Pharmaceutical combination | |
| GB0129397D0 (en) | Pharmaceutical combination | |
| IL158587A0 (en) | Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof | |
| HUP0200253A3 (en) | Pharmaceutical compositions for combination therapy | |
| GB0209356D0 (en) | Medical facemask | |
| GB0129395D0 (en) | Pharmaceutical combination | |
| GB0410094D0 (en) | Human RAS interacting protein | |
| GB0410147D0 (en) | Human angiomotin-like protein 1 | |
| GB0128138D0 (en) | Pharmaceutical use | |
| GB0122061D0 (en) | Vision therapy | |
| IL145821A0 (en) | Oral-nasal cannula | |
| GB0201681D0 (en) | Human ralgds-like protein 3 | |
| GB0201819D0 (en) | Human posh-like protein 1 | |
| GB0114687D0 (en) | Medical laser device | |
| GB0128865D0 (en) | Diathermy forceps connection means | |
| IL144389A0 (en) | Medical database |